Patents Assigned to Merck Sharp & Dohme LLC
-
Publication number: 20250243491Abstract: Disclosed herein are short interfering RNA (siRNA) molecules that downregulate expression of PNPLA3 or variants thereof. The siRNA molecules comprise modified nucleotides and uses thereof. The siRNA molecules may be double stranded and comprise modified nucleotides, such as 2?-O-methyl nucleotides and 2?-fluoro nucleotides, and ligands.Type: ApplicationFiled: September 1, 2022Publication date: July 31, 2025Applicants: Aligos Therapeutics, Inc., Merck Sharp & Dohme LLCInventors: Leonid BEIGELMAN, Xuan LUONG, Saul MARTINEZ MONTERO, Aneerban BHATTACHARYA, Jerome DEVAL
-
Publication number: 20250230185Abstract: Provided herein are methods of separating host cell lipases from a production protein in chromatographic processes and methods of improving polysorbate-80 stability in a production protein formulation by separating host cell lipases from the production protein using chromatographic processes.Type: ApplicationFiled: January 16, 2025Publication date: July 17, 2025Applicant: Merck Sharp & Dohme LLCInventors: Rebecca A. Chmielowski, Francis K. Insaidoo, Justin B. Miller, David J. Roush, Darshini Shah, John P. Welsh
-
Publication number: 20250223259Abstract: The present invention provides a compound of Formula I wherein A, M, R1, R2, R3a, R3b, and subscripts m and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: January 5, 2023Publication date: July 10, 2025Applicant: Merck Sharp & Dohme LLCInventors: Brian T. Campbell, Wonsuk Chang, Timothy J. Hartingh, Danielle M. Hurzy, Michael J. Kelly, III, Franca-Maria Klingler, Mark E. Layton, John A. McCauley, Christopher Charles Nawrat, Craig A. Parish, James J. Perkins, Anthony J. Roecker, Manuel de Lera Ruiz, John D. Schreier, Valerie W. Shurtleff, Jing Su, Quang T. Truong
-
Publication number: 20250223290Abstract: Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.Type: ApplicationFiled: December 12, 2024Publication date: July 10, 2025Applicant: Merck Sharp & Dohme LLCInventors: Zachary G. Brill, Donna A.A.W. Hayes, Tom M. Lam, Kyle S. McClymont, Bryan S. Matsuura, Rohan Rajiv Merchant, Anilkumar G. Nair, Ning Qi
-
Patent number: 12350270Abstract: Methods of treating malaria comprising administration of compounds of Formula (I?) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.Type: GrantFiled: July 21, 2020Date of Patent: July 8, 2025Assignees: MSD R&D (China) Co. Ltd., The Walter and Eliza Hall Institute of Medical Research, Merck Sharp & Dohme LLCInventors: John A. McCauley, Alan F. Cowman, Manuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, David B. Olsen, Brad Sleebs, Jennifer K. Thompson, Tony Triglia, Dongmei Zhan, Cailing Zhang, Lianyun Zhao
-
Patent number: 12351630Abstract: The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.Type: GrantFiled: October 8, 2021Date of Patent: July 8, 2025Assignee: Merck Sharp & Dohme LLCInventors: Edward Bowman, Maribel Beaumont, Marie-Ange Buyse, Carlo Boutton, Bruno Dombrecht, Robert A. Kastelein, David Vlerick
-
Publication number: 20250215464Abstract: The present disclosure provides enzymes derived from the fungi Fusarium oxysporum c8D (“FoPip4H enzymes”) having improved properties as compared to a naturally occurring wild-type enzyme including the capability of hydroxylating certain substituted indanones to provide optically pure 3-hydroxyindanones. Also provided are polynucleotides encoding the FoPip4H enzymes, host cells capable of expressing the FoPip4H enzymes, and processes for using the FoPip4H enzymes to synthesize (R)-4-fluoro-3-hydroxy-7-(methylsulfonyl)-2, 3-dihydro-1H-inden-1-one, a useful intermediate in the synthesis of belzutifan.Type: ApplicationFiled: July 5, 2023Publication date: July 3, 2025Applicant: Merck Sharp & Dohme LLCInventors: Wai Ling Cheung-Lee, Daniel A. DiRocco, Agnieszka Gil, Kaori Hiraga, Jungchul Kim, Joshua Kolev, Birgit Kosjek, Kevin M. Maloney, Nastaran Salehi Marzijarani, John McIntosh, Jonathan P. McMullen, Jeffrey C. Moore, Grant S. Murphy, Weilan Pan, Juan E. Velasquez Velez, Deeptak Verma, Matthew S. Winston, Li Xiao, Victoria Zhang
-
Patent number: 12344595Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.Type: GrantFiled: October 28, 2019Date of Patent: July 1, 2025Assignee: Merck Sharp & Dohme LLCInventors: Michael J. Breslin, Christopher James Bungard, Harry R. Chobanian, Kristen L. G. Jones, Mark E. Layton, Jian Liu, James J. Perkins, Jeffrey William Schubert, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
-
Patent number: 12344670Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.Type: GrantFiled: December 20, 2023Date of Patent: July 1, 2025Assignees: Agenus Inc., Merck Sharp & Dohme LLCInventors: Milan Blanusa, Barbara Joyce-Shaikh, Andrea Claudia Schuster, Kornelia Schultze, Luis A. Zuniga
-
Patent number: 12344616Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.Type: GrantFiled: October 21, 2019Date of Patent: July 1, 2025Assignee: Merck Sharp & Dohme LLCInventors: Amjad Ali, John S. Debenham, Cheng Zhu
-
Publication number: 20250205328Abstract: The present disclosure provides, among other things, a vaccine composition that includes HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82, where the vaccine composition provides enhanced or comparable HPV vaccine response in comparison to a similar multiple-dose vaccine.Type: ApplicationFiled: March 23, 2023Publication date: June 26, 2025Applicant: Merck Sharp & Dohme LLCInventors: Akhilesh Bhambhani, Donna M. Williams
-
Publication number: 20250195511Abstract: Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control, and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.Type: ApplicationFiled: December 12, 2024Publication date: June 19, 2025Applicant: Merck Sharp & Dohme LLCInventors: Zachary G. Brill, Donna A.A.W. Hayes, Tom M. Lam, Kyle S. McClymont, Bryan S. Matsuura, Rohan Rajiv Merchant, Anilkumar G. Nair, Ning Qi
-
Patent number: 12331018Abstract: The present invention is directed to pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: February 11, 2020Date of Patent: June 17, 2025Assignee: Merck Sharp & Dohme LLCInventors: Stephane L. Bogen, Michael J. Breslin, Dane James Clausen, Anthony Ginnetti, Michael T. Rudd, Shawn J. Stachel, Craig A. Stump, Dexi Yang
-
Patent number: 12331022Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammationType: GrantFiled: April 27, 2020Date of Patent: June 17, 2025Assignee: Merck Sharp & Dohme LLCInventors: Ian M. Bell, Brian T. Campbell, Brendan M. Crowley, James Fells, Kenneth J. Leavitt, Anthony J. Roecker, Andrew John Harvey, Belinda C. Huff, Dharam Paul, Christophe Morice, Christophe Joseph, Patrick Bazzini, Jean-Marie Contreras, Fabrice Garrido, Aurelie Witzel
-
Patent number: 12319735Abstract: The present invention provides co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.Type: GrantFiled: November 6, 2019Date of Patent: June 3, 2025Assignee: Merck Sharp & Dohme LLCInventors: Valentyn Antochshuk, Preeti G. Desai, Yogita Krishnamachari, Sahil S. Sangani
-
Patent number: 12319671Abstract: The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.Type: GrantFiled: June 1, 2020Date of Patent: June 3, 2025Assignee: Merck Sharp & Dohme LLCInventors: Hua Zhou, John J. Acton, III, Michael J. Ardolino, Yi-Heng Chen, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, William P. Kaplan, Solomon D. Kattar, Mitchell H. Keylor, Derun Li, Kaitlyn Marie Logan, Min Lu, Gregori J. Morriello, Santhosh F. Neelamkavil, Barbara Pio, Nunzio Sciammetta, Vladimir Simov, Jing Su, Luis Torres, Xin Yan
-
Publication number: 20250171447Abstract: In its many embodiments, the invention provides compounds of structural Formula (I): (I), and pharmaceutically acceptable salts thereof, wherein, ring A, R1, R2 and R3 are as defined herein, and pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents). The invention further provides methods for the preparation and use of the compounds of the invention, or a pharmaceutically acceptable salt thereof, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.Type: ApplicationFiled: February 14, 2023Publication date: May 29, 2025Applicant: Merck Sharp & Dohme LLCInventors: Amjad Ali, Zachary G. Brill, Alec Hiroshi Christian, Duane E. DeMong, Jared N. Cumming, Jenny Lorena Rico Duque, Elisabeth T. Hennessy, Derun Li, Yeon-Hee Lim, Christopher W. Plummer, Jing Su
-
Publication number: 20250171467Abstract: The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and/or other glucosylceramide-based glycosphingolipids (GSLs).Type: ApplicationFiled: March 8, 2023Publication date: May 29, 2025Applicant: Merck Sharp & Dohme LLCInventors: Anthony J. Roecker, Ling Tong
-
Publication number: 20250170133Abstract: The application relates to a pharmaceutical combination or combinational therapy comprising a therapeutically effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one second agent, or a pharmaceutically acceptable salt thereof, for use in the treatment of a BTK-mediated disease or disorder.Type: ApplicationFiled: March 27, 2023Publication date: May 29, 2025Applicants: Merck Sharp & Dohme LLC, ArQule Inc., Ohio State Innovation FoundationInventors: Mohammed Z.H. Farooqui, Patricia Marinello, Anson Kunjachan Abraham, Sudharshan Eathiraj, Brian E. Schwartz, Yi Yu, John C. Byrd, Elizabeth M. Muhowski, Jennifer A. Woyach
-
Patent number: 12310945Abstract: The present disclosure is directed to cyclohexylglycine derivatives of Formula I and their use as HIV-infected cell kill agents which accelerate the death of HIV GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells.Type: GrantFiled: December 22, 2022Date of Patent: May 27, 2025Assignee: Merck Sharp & Dohme LLCInventors: Douglas C. Beshore, Keith P. Moore, Rajan Anand, Remond Moningka, William D. Shipe